dCTPase protein
class dCTPase Inhibitors
selective dCTPase inhibitor
cancer treatment
business strategy
business plan
overall business programme
cancer cells
secure IP
planned business model
cytidine analogue treatment
GEnetic NEtworks
TH1217
IP rights
new company
ERC grant
anti-CAncer Drug Development
treatment of hematological Cancers
cost of clinical trials
nucleoside analogue therapy
preclinical development
technical analysis
market analysis
new therapies
commercial potential
non-profit foundation
degradation of nucleoside analogues
potential commercialization partners
long term support
nontransformed dividing cells
company Oxcia AB
IMPD application
regulatory bodies
clinicians
combination
tool
siRNA screening
low nM potent
funding agencies
cell death
translational science
viability
Medical Products Agency
favourable pharmacokinetic properties
collaboration
effort
role
target
enzymatic high-throughput assay
exclusive license
compounds
increased toxicity
apoptosis
direction
house medicinal chemistry
IC50
DNA repair
hits
investments
RNAi approach
replication
patients
studies
Î¼M